Neuland Laboratories Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/24umwwenf629i6baridtoi6p.pdf

Key Takeaways


Business Mix Transformation

Saharsh Davuluri: "…the performance of the recent quarters is a sustainable performance. But at the same time, it's difficult to quantify whether it will be replicated in specific quarters or not."

CMS Pipeline & Customer Dynamics

Saharsh Davuluri: "…we continue to have these conversations with our CMS customers and we've been, you know, advised to keep the information very, very confidential. And therefore, you know, we're not really even comfortable disclosing therapeutic area because, again, it could potentially lead to more follow-up questions about these molecules."

Biotech Funding & Demand Environment


Margins & Operating Leverage


Capacity & Capex

Sucheth Davuluri: "Our strategy is to make sure that we never actually run out of capacity."

Peptides & New Capabilities

Saharsh Davuluri: "I think it's still a little difficult and early to talk about the economics, the commercials of it, because I think when you start off the development of a complex generic like this, your costs will be high, and it will be very difficult to figure out how viable it will be."

Regulatory & Quality


Guidance & Commitments

CommitmentSpecificsTimeline
API commercializationTwo more APIs to become commercialNext 12 to 18 months
Biotech funding recoveryFunding environment could possibly changeNext 6-9 months
Capacity expansion (Unit 3)Finite capacity creation within existing facilities12-15 months from decision
Capacity sufficiencySufficient capacities maintainedNext couple of years
Working capitalKeep at ~110 days of revenueMoving forward
Capex run-rateClose to INR 100 crores annually for facility upgradesOngoing

Key Metrics

MetricQ1 FY24
Total income₹365 cr, +64.7% YoY; Q4FY23 was ₹415.1 cr
EBITDA₹99.3 cr, margin 27.2%, up 14,410 bps YoY
Gross margin55.2%, vs 53.6% in Q1FY23 and 54.1% in Q4FY23
Profit after tax₹62.2 cr, vs ₹9.8 cr in Q1FY23
EPS₹48.5 per share
Free cash flow₹40.7 cr
Net debt₹24.4 cr
CMS revenue share44% of total revenue, vs 31% in Q1FY23
Working capital cycle118 days, improved from 141 days in Q4FY23
Capex (quarter)₹11.7 cr invested
Annual capex budget~₹100 cr per year
Capacity utilizationUnit 1 and Unit 2 at ~90%+, Unit 3 at ~60%
Headcount~1,700, up from ~1,600
Employee benefit expense+24% YoY, driven by increments and headcount increase